A Revolutionary Diagnostic Test for Multiple Myeloma & MGUS
Multiple Myeloma is the second most common haematological cancer worldwide with approximately 110,000 patients in the USA, European Union and Japan alone.
Current diagnosis and ongoing monitoring of Multiple Myeloma and its preceding condition, MGUS, requires repeated bloodtests, X-rays and bone marrow biopsies which are expensive, stressful, require specialist resource and sometimes lack diagnostic clarity.
The Solution
This miRNA based test is set to simplify this treatment pathway, reduce clinic visits and patient stress in addition to delivering more accurate prognosis and likely progression of the illness.The Multiple Myeloma Biomarker Test has potential to replace several stages of the diagnosis pathway that patients and physicians can find themselves repeating for years. Using a simple blood sample, this test gives further and accurate information on the status of MGUS and multiple myeloma development.
Features and Benefits
For Healthcare Providers
- Reduction of bone biopsy need
- Increased diagnosis information
- Consultant Haemotologist time saving for disease monitoring
- Simplification of disease progression check-ups
- Opportunity to screen, simplify diagnosis and monitor frequently
For Pharmaceuticals
- Potential for 370,000* tests each year in UK alone
- Seamless integration into existing practices and pathways
- Potential to aid the development of new Myeloma drugs
- Growing market need
For Patients
- Less frequent clinic visits lets patients get on with their lives
- Far less painful than biopsy
- Familiar and innocuous test reduces patient stress
Opportunity
Developed at The University of Sussex, the test has been substantiated against control groups and we are now seeking a commercial partner to accelerate further development and commercialise the resulting diagnostic.
For more information download our info-sheet or contact us.